Gemcitabine (1000 mg/m2)

DRUG11 trials

Sponsors

SciClone Pharmaceuticals, Inhibrx Biosciences, Inc, Fudan University, National Cancer Institute, Egypt, Hospital Universitario Dr. Jose E. Gonzalez

Conditions

Advanced Pancreatic CancerBiliary Tract Cancer (BTC)Diffuse Pleural Mesothelioma (DPM)Gastric CancerHead and Neck CancerHigh-grade B-cell LymphomaLarge B-Cell Lymphoma (LBCL)Melanoma

Phase 1

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

RecruitingNCT04198766

Inhibrx Biosciences, IncGastric Cancer, Head and Neck Cancer, Melanoma +5

Start: 2019-12-10End: 2033-07-01Target: 340Updated: 2026-07-29

Phase 2

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

TerminatedNCT00550004

SciClone PharmaceuticalsPancreatic Cancer

Start: 2007-09-30End: 2009-10-31Target: 153Updated: 2011-06-08

Gemcitabine as Maintenance Treatment for Diffuse Pleural Mesothelioma

CompletedNCT07411144

National Cancer Institute, EgyptDiffuse Pleural Mesothelioma (DPM)

Start: 2020-03-15End: 2023-03-15Updated: 2026-02-13

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

RecruitingNCT07451652

Hospital Universitario Dr. Jose E. GonzalezRelapsed/Refractory Diffuse Large B Cell Lymphoma

Start: 2026-03-17End: 2027-09-01Target: 10Updated: 2026-04-01

A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.

Not yet recruitingNCT07578337

Nelum CorpAdvanced Pancreatic Cancer, Untreated

Start: 2026-07-15End: 2029-02-28Target: 40Updated: 2026-05-13

Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma

Not yet recruitingNCT07774234

The First Affiliated Hospital of Soochow UniversityHigh-grade B-cell Lymphoma, Large B-Cell Lymphoma (LBCL)

Start: 2026-08-20End: 2030-08-20Target: 39Updated: 2026-08-19

Trial of First-line Gemcitabine and Nab-paclitaxel With or Without L-glutamine in Advanced Pancreatic Cancer

Not yet recruitingNCT07864571

Jun Gong, MDPancreatic Cancer

Start: 2026-12-01End: 2028-12-01Target: 200Updated: 2026-10-08

Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma

Not yet recruitingNCT07902713

Sun Yat-sen UniversityNasopharyngeal Carcinoma (NPC)

Start: 2026-11-01End: 2029-12-31Target: 30Updated: 2026-10-29

Phase 3

Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes

Not yet recruitingNCT07272109

Fudan UniversityPancreatic Cancer

Start: 2026-01-01End: 2028-12-30Target: 210Updated: 2025-12-15

Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma

RecruitingNCT07498907

Peking University First HospitalUpper Tract Urothelial Carcinoma

Start: 2026-05-01End: 2034-03-01Target: 192Updated: 2026-09-28

Phase 4

A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer

RecruitingNCT07619235

Xianglin YuanBiliary Tract Cancer (BTC)

Start: 2026-06-10End: 2028-12-31Target: 32Updated: 2026-09-15

Related Papers

Gemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study

BMC Cancer2026-03-26

INBRX-106, a novel Hexavalent OX40 agonist, potentiates T-cell receptor clustering, leading to improved activation and potent anti-tumor responses 3058

The Journal of Immunology2025-11-01

HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥20.

Journal of Clinical Oncology2025-05-28

INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering

Journal for ImmunoTherapy of Cancer2025-05-014 citations

748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors

Regular and Young Investigator Award Abstracts2023-10-311 citations

1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice

Regular and Young Investigator Award Abstracts2023-10-31

856 INBRX-106: a novel hexavalent anti-OX40 agonist for the treatment of solid tumors

Regular and Young Investigator Award Abstracts2021-11-019 citations

RP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients.

2011-07-2271 citations